Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure o… Read more
Market Cap & Net Worth: Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a market capitalization of $660.94 Million ($660.94 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9707 globally and #4608 in its home market, demonstrating a -6.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lexicon Pharmaceuticals Inc's stock price $1.56 by its total outstanding shares 423680611 (423.68 Million).
Lexicon Pharmaceuticals Inc Market Cap History: 2015 to 2026
Lexicon Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $5.64 Billion to $660.94 Million (-17.29% CAGR).
Index Memberships
Lexicon Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.03% | #265 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1012 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.51 Trillion | 0.04% | #158 of 263 |
Weight: Lexicon Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lexicon Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lexicon Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.78x
Lexicon Pharmaceuticals Inc's market cap is 9.78 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.86 Billion | $83.34 Million | -$141.43 Million | 70.31x | N/A |
| 2017 | $4.19 Billion | $90.33 Million | -$129.05 Million | 46.34x | N/A |
| 2018 | $2.81 Billion | $63.21 Million | -$120.55 Million | 44.51x | N/A |
| 2019 | $1.76 Billion | $322.07 Million | $130.13 Million | 5.46x | 13.51x |
| 2020 | $1.45 Billion | $24.00 Million | -$58.57 Million | 60.39x | N/A |
| 2021 | $1.67 Billion | $298.00K | -$87.76 Million | 5601.68x | N/A |
| 2022 | $809.23 Million | $139.00K | -$101.94 Million | 5821.80x | N/A |
| 2023 | $648.23 Million | $1.20 Million | -$177.12 Million | 538.40x | N/A |
| 2024 | $312.89 Million | $31.08 Million | -$200.40 Million | 10.07x | N/A |
| 2025 | $487.23 Million | $49.80 Million | -$50.34 Million | 9.78x | N/A |
Competitor Companies of LXRX by Market Capitalization
Companies near Lexicon Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Lexicon Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Lexicon Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Lexicon Pharmaceuticals Inc's market cap moved from $5.64 Billion to $ 660.94 Million, with a yearly change of -17.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $660.94 Million | +35.65% |
| 2025 | $487.23 Million | +55.72% |
| 2024 | $312.89 Million | -51.73% |
| 2023 | $648.23 Million | -19.90% |
| 2022 | $809.23 Million | -51.52% |
| 2021 | $1.67 Billion | +15.20% |
| 2020 | $1.45 Billion | -17.59% |
| 2019 | $1.76 Billion | -37.50% |
| 2018 | $2.81 Billion | -32.79% |
| 2017 | $4.19 Billion | -28.56% |
| 2016 | $5.86 Billion | +3.91% |
| 2015 | $5.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Lexicon Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $660.94 Million USD |
| MoneyControl | $660.94 Million USD |
| MarketWatch | $660.94 Million USD |
| marketcap.company | $660.94 Million USD |
| Reuters | $660.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.